Virtu Financial LLC Grows Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Virtu Financial LLC raised its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 48.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,463 shares of the company’s stock after acquiring an additional 2,419 shares during the period. Virtu Financial LLC’s holdings in Janux Therapeutics were worth $339,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Summit Securities Group LLC bought a new stake in Janux Therapeutics during the second quarter worth approximately $29,000. Amalgamated Bank boosted its holdings in shares of Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares during the period. Plato Investment Management Ltd bought a new position in shares of Janux Therapeutics during the 2nd quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after buying an additional 339 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Janux Therapeutics during the 2nd quarter valued at $151,000. 75.39% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, December 3rd. Stifel Nicolaus upped their target price on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Scotiabank raised their price target on Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 4th. Leerink Partners upped their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday, December 3rd. Finally, Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $89.90.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $61.56 on Tuesday. The stock’s fifty day moving average is $53.08 and its two-hundred day moving average is $46.88. The firm has a market capitalization of $3.23 billion, a P/E ratio of -52.62 and a beta of 3.29. Janux Therapeutics, Inc. has a fifty-two week low of $7.79 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. The firm’s revenue was down 82.6% on a year-over-year basis. As a group, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Insider Activity

In other news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $46.24, for a total transaction of $44,297.92. Following the completion of the transaction, the insider now directly owns 6,887 shares of the company’s stock, valued at approximately $318,454.88. The trade was a 12.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. purchased 1,200,000 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The stock was purchased at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the purchase, the director now directly owns 9,317,246 shares of the company’s stock, valued at $416,946,758.50. The trade was a 14.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 192,032 shares of company stock valued at $9,512,515. 29.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.